Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
NCT ID: NCT06350890
Last Updated: 2025-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
408 participants
INTERVENTIONAL
2023-11-05
2025-08-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients who complete the double-blind treatment period will enter an open-label extension period where all patients will receive HTD1801 1000 mg BID for an additional 28 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HTD1801
Administered orally twice daily (BID)
HTD1801
HTD1801 1000 mg administered orally BID as four capsules
Placebo
Administered orally BID
Placebo
Matching placebo administered orally BID as four capsules
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HTD1801
HTD1801 1000 mg administered orally BID as four capsules
Placebo
Matching placebo administered orally BID as four capsules
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have followed dietary and exercise interventions for at least 8 weeks prior to screening
* If used any glucose-lowering drugs within the 8 weeks prior to screening such use was ≤7 days and was discontinued at least 4 weeks prior to screening
* Have HbA1c ≥7.5% to ≤11.0% (screening) and ≥7.0% to ≤10.5% (pre-randomization)
* Have fasting plasma glucose ≤13.9 mmol/L (screening and pre-randomization)
* Have a body mass index ≥19.0 kg/m\^2 to ≤35.0 kg/m\^2
Exclusion Criteria
* Have had any acute diabetic complications within 12 months prior to screening
* Have had any Grade 3 hypoglycemic event within 12 months prior to screening
* Have had proliferative retinopathy or macular degeneration, severe diabetic neuropathy, or diabetic foot
* Have been taking any weight loss medication or dietary supplement, have participated in a weight loss program, or have adhered to a special diet within 12 weeks prior to screening
* Have used insulin or an insulin analogue for more than 14 days within 12 months prior to screening
* Have used any hypoglycemic drug during the 4-week run-in period prior to randomization
* Have had weight gain or loss ≥5% during the 4-week run-in period prior to randomization
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shenzhen HighTide Biopharmaceutical Ltd.
UNKNOWN
HighTide Biopharma Pty Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kui Liu, MD
Role: STUDY_DIRECTOR
Shenzhen HighTide Biopharmaceutical Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xuancheng People's Hospital
Xuancheng, Anhui, China
Beijing Pinggu Hospital
Beijing, Beijing Municipality, China
Fuwai Hospital, CAMS & PUMC
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Peking University People's Hospital
Beijing, Beijing Municipality, China
Chongqing University Three Gorges Hospital
Chongqing, Chongqing Municipality, China
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Huizhou Municipal Central Hospital
Huizhou, Guangdong, China
Shenzhen People's Hospital
Shenzhen, Guangdong, China
Liuzhou People's Hospital
Liuchow, Guangxi, China
Cangzhou Central Hospital
Cangzhou, Hebei, China
Handan First Hospital
Handan, Hebei, China
Hengshui People's Hospital (Harrison International Peace Hospital)
Hengshui, Hebei, China
Hebei Petro China Central Hospital
Langfang, Hebei, China
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The First Hospital of Qiqihar
Qiqihar, Heilongjiang, China
The Third Affiliated Hospital of Qiqihar Medical University
Qiqihar, Heilongjiang, China
The First Affiliated Hospital of Henan University of Science & Technology (Jinghua)
Luoyang, Henan, China
The First Affiliated Hospital of Henan University of Science & Technology (Kaiyuan)
Luoyang, Henan, China
The First Affiliated Hospital of Nanyang Medical College
Nanyang, Henan, China
Zhumadian Central Hospital
Zhumadian, Henan, China
Huangshi Central Hospital
Huangshi, Hubei, China
Jingzhou Central Hospital
Jingzhou, Hubei, China
The Central Hospital of Wuhan
Wuhan, Hubei, China
The First People's Hospital of Changde City
Changde, Hunan, China
Hunan Provincial People's Hospital
Changsha, Hunan, China
Yueyang People's Hospital
Yueyang, Hunan, China
Baotou City Central Hospital
Baotou, Inner Mongolia, China
Inner Mongolia People's Hospital
Hohhot, Inner Mongolia, China
The First People's Hospital of Changzhou
Changzhou, Jiangsu, China
Huai'an First People's Hospital
Huai'an, Jiangsu, China
The Second People's Hospital of Lianyungang
Lianyungang, Jiangsu, China
Nanjing Drum Tower Hospital - The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
Nanjing First Hospital
Nanjing, Jiangsu, China
Nanjing Jiangning Hospital
Nanjing, Jiangsu, China
Sir Run Run Shaw Hospital Nanjing Medical University
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China
Pingxiang People's Hospital
Pingxiang, Jiangxi, China
The Second Hospital of Jilin University
Changchun, Jilin, China
Tonghua Central Hospital
Tonghua, Jilin, China
Panjin Liaohe Oilfield Gem Flower Hospital
Panjin, Liaoning, China
The Sixth People's Hospital of Shenyang
Shenyang, Liaoning, China
Qinghai Provincial People's Hospital
Xining, Qinghai, China
The Second Affiliated Hospital of Shaanxi University of Chinese Medicine
Xianyang, Shaanxi, China
Jinan Central Hospital
Jinan, Shandong, China
Liaocheng People's Hospital
Liaocheng, Shandong, China
Shanghai East Hospital of Tongji University
Shanghai, Shanghai Municipality, China
The Third People's Hospital of Datong
Datong, Shanxi, China
Yuncheng Central Hospital
Yuncheng, Shanxi, China
People's Hospital of Tianjin
Tianjin, Tianjin Municipality, China
The First People's Hospital of Kashi
Kashgar, Xinjiang, China
The Second Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Huzhou Central Hospital
Huzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HTD1801.PCT105
Identifier Type: -
Identifier Source: org_study_id